FDA Puts Hold on KalVista’s Phase 2 Trial of KVD824 for HAE Attacks

FDA Puts Hold on KalVista’s Phase 2 Trial of KVD824 for HAE Attacks

292700

FDA Puts Hold on KalVista’s Phase 2 Trial of KVD824 for HAE Attacks

The U.S. Food and Drug Administration (FDA) has placed a hold on KalVista Pharmaceuticals’ proposed Phase 2 trial of KVD824 — which the developer had expected to launch by the end of June.  The trial is intended to test KVD824 as a potential preventive treatment for hereditary angioedema (HAE) swelling attacks. KalVista had submitted an investigational new drug application earlier this year, asking the FDA for permission to conduct the trial and assess the experimental oral…

You must be logged in to read/download the full post.